Ropanicant

Phase 2Small molecule

SSuven Life Sciences Limited

Ropanicant is one of 46 small molecule programs targeting Efficacy and Safety. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyActive, not recruiting

Efficacy and SafetyPhase 2

Active, not recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Savaysa

Daiichi Sankyo

Phase 3

3 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 4

Rapamune

PPrism Pharmaceuticals

Phase 3

5 5

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Becotatug Vedotin

FFudan University

Phase 3

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 10

VAY736

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Active, not recruiting·SSuven Life Sciences Limited·Phase 2·NCT06836063·195 enrolled

Major Depressive Disorder1 trial

An Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder

Completed·SSuven Life Sciences Limited·Phase 2·NCT06126497·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ropanicant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ropanicant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ropanicant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suven Life Sciences Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSuven Life Sciences Limited

Ropanicant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News